Rigel, Bristol-Myers Squibb partner to develop cancer immunotherapies
The cancer immunotherapies will be developed and commercialized by using Rigel’s small molecule TGF beta receptor kinase inhibitors range. Through the partnership, Bristol-Myers Squibb will secure exclusive, global